Sly Saint
Senior Member (Voting Rights)
https://journals.lww.com/americanth...ng_Drugs_for_Post_COVID_19_Fatigue.97973.aspx
pdf only
pdf only
Experts have suggested that the post–COVID-19
fatigue syndrome (PCFS) shows great similarity with
myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS),4 a poorly understood condition that has been
described after a variety of viral infections and shares
many clinical and prognostic features with fibromyalgia.
Pharmacological interventions in ME/CFS have been
disappointing, a fate that might await PCFS as well.
Yet the stakes are clearly higher for PCFS. The prevalence
of ME/CFS is approximately 0.75%.5 On the other
hand, a review of 18 cross-sectional studies indicated that
32% of individuals with a history of patients with
COVID-19 reported fatigue 28 weeks after the onset of
their acute illness.6 Given the fact that there are 48.6
million people in the United States who survived a documented
COVID-19 infection,7 the prevalence of PCFS can
be conservatively estimated at 4.7% or 15.5 million in
December 2021.